A detailed history of Dn B Asset Management As transactions in Incyte Corp stock. As of the latest transaction made, Dn B Asset Management As holds 33,158 shares of INCY stock, worth $2.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
33,158
Previous 30,185 9.85%
Holding current value
$2.11 Million
Previous $1.72 Million 16.93%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$51.18 - $63.75 $152,158 - $189,528
2,973 Added 9.85%
33,158 $2.01 Million
Q1 2024

Apr 12, 2024

SELL
$56.55 - $66.59 $194,588 - $229,136
-3,441 Reduced 10.23%
30,185 $1.72 Million
Q4 2023

Jan 04, 2024

SELL
$52.16 - $64.19 $4.08 Million - $5.02 Million
-78,261 Reduced 69.95%
33,626 $2.11 Million
Q3 2023

Oct 13, 2023

BUY
$57.77 - $65.93 $3.95 Million - $4.51 Million
68,375 Added 157.14%
111,887 $6.46 Million
Q2 2023

Jul 06, 2023

BUY
$60.95 - $75.51 $256,660 - $317,972
4,211 Added 10.71%
43,512 $2.71 Million
Q1 2023

Apr 20, 2023

BUY
$70.23 - $86.01 $256,760 - $314,452
3,656 Added 10.26%
39,301 $2.84 Million
Q4 2022

Jan 12, 2023

SELL
$67.18 - $84.11 $25,125 - $31,457
-374 Reduced 1.04%
35,645 $2.86 Billion
Q3 2022

Oct 11, 2022

BUY
$66.18 - $82.86 $137,522 - $172,183
2,078 Added 6.12%
36,019 $0
Q2 2022

Jul 08, 2022

BUY
$66.18 - $83.18 $179,943 - $226,166
2,719 Added 8.71%
33,941 $2.58 Billion
Q1 2022

Apr 08, 2022

BUY
$66.02 - $79.71 $145,508 - $175,680
2,204 Added 7.6%
31,222 $0
Q4 2021

Jan 12, 2022

BUY
$63.34 - $74.11 $66,570 - $77,889
1,051 Added 3.76%
29,018 $0
Q3 2021

Oct 15, 2021

SELL
$68.67 - $84.02 $3.96 Million - $4.85 Million
-57,725 Reduced 67.36%
27,967 $0
Q2 2021

Jul 06, 2021

BUY
$79.87 - $87.53 $1.62 Million - $1.77 Million
20,245 Added 30.93%
85,692 $7.21 Billion
Q1 2021

Apr 15, 2021

BUY
$76.02 - $100.5 $3.16 Million - $4.17 Million
41,531 Added 173.65%
65,447 $0
Q4 2020

Jan 19, 2021

BUY
$80.74 - $97.7 $140,568 - $170,095
1,741 Added 7.85%
23,916 $0
Q3 2020

Oct 14, 2020

BUY
$85.07 - $109.69 $57,847 - $74,589
680 Added 3.16%
22,175 $0
Q2 2020

Jul 08, 2020

BUY
$74.18 - $108.93 $312,149 - $458,377
4,208 Added 24.34%
21,495 $2.23 Billion
Q1 2020

Apr 17, 2020

SELL
$63.18 - $85.97 $214,938 - $292,469
-3,402 Reduced 16.44%
17,287 $0
Q4 2019

Jan 13, 2020

BUY
$73.04 - $95.72 $189,611 - $248,489
2,596 Added 14.35%
20,689 $0
Q3 2019

Oct 16, 2019

BUY
$72.82 - $86.52 $67,504 - $80,204
927 Added 5.4%
18,093 $0
Q2 2019

Jul 08, 2019

SELL
$73.52 - $88.7 $136,379 - $164,538
-1,855 Reduced 9.75%
17,166 $0
Q1 2019

Apr 11, 2019

SELL
$63.56 - $88.17 $151,209 - $209,756
-2,379 Reduced 11.12%
19,021 $0
Q4 2018

Jan 15, 2019

BUY
$58.5 - $69.94 $64,350 - $76,934
1,100 Added 5.42%
21,400 $0
Q3 2018

Oct 10, 2018

BUY
$61.75 - $74.23 $18,525 - $22,269
300 Added 1.5%
20,300 $0
Q2 2018

Jul 06, 2018

BUY
$60.85 - $83.98 $66,935 - $92,378
1,100 Added 5.82%
20,000 $0
Q1 2018

Apr 11, 2018

SELL
$83.06 - $100.98 $1.05 Million - $1.28 Million
-12,700 Reduced 40.19%
18,900 $0
Q4 2017

Jan 10, 2018

BUY
$93.56 - $116.6 $346,172 - $431,420
3,700 Added 13.26%
31,600 $0
Q3 2017

Oct 11, 2017

BUY
$109.15 - $138.27 $3.05 Million - $3.86 Million
27,900
27,900 $0

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $14.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Dn B Asset Management As Portfolio

Follow Dn B Asset Management As and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.